BRPI0814097A2 - Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado - Google Patents

Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado

Info

Publication number
BRPI0814097A2
BRPI0814097A2 BRPI0814097-9A2A BRPI0814097A BRPI0814097A2 BR PI0814097 A2 BRPI0814097 A2 BR PI0814097A2 BR PI0814097 A BRPI0814097 A BR PI0814097A BR PI0814097 A2 BRPI0814097 A2 BR PI0814097A2
Authority
BR
Brazil
Prior art keywords
modified
amino acid
terminal amino
peptide derivative
insulinotropic peptide
Prior art date
Application number
BRPI0814097-9A2A
Other languages
English (en)
Inventor
Dae Hae Song
Chang Ki Lim
Young Hoon Kim
Se Chang Kwon
Gwan Sun Lee
Sung Min Bae
Sung Youb Jung
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of BRPI0814097A2 publication Critical patent/BRPI0814097A2/pt
Publication of BRPI0814097A8 publication Critical patent/BRPI0814097A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0814097A 2007-07-16 2008-07-16 Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado BRPI0814097A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20070071071 2007-07-16
EP60991155 2007-11-29
PCT/KR2008/004170 WO2009011544A2 (en) 2007-07-16 2008-07-16 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified

Publications (2)

Publication Number Publication Date
BRPI0814097A2 true BRPI0814097A2 (pt) 2015-02-03
BRPI0814097A8 BRPI0814097A8 (pt) 2016-01-12

Family

ID=40260219

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814097A BRPI0814097A8 (pt) 2007-07-16 2008-07-16 Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado

Country Status (21)

Country Link
US (1) US9422349B2 (pt)
EP (4) EP2176289A4 (pt)
JP (7) JP2009019027A (pt)
KR (1) KR101231431B1 (pt)
CN (2) CN104672319B (pt)
AR (1) AR067555A1 (pt)
AU (1) AU2008276762A1 (pt)
BR (1) BRPI0814097A8 (pt)
CA (3) CA2693154C (pt)
DK (1) DK2390265T3 (pt)
ES (3) ES2528347T3 (pt)
IL (1) IL203288A (pt)
MY (1) MY167486A (pt)
NZ (3) NZ596828A (pt)
PH (2) PH12014500922A1 (pt)
PT (1) PT2390265E (pt)
RU (1) RU2442792C2 (pt)
SG (3) SG183033A1 (pt)
TW (3) TWI524896B (pt)
WO (1) WO2009011544A2 (pt)
ZA (1) ZA201000125B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
MX2011009803A (es) * 2009-03-20 2011-09-30 Hanmi Holdings Co Ltd Metodo para preparar un polipeptido conjugado fisiologicamente activo en un sitio especifico.
EP2504021A4 (en) 2009-11-23 2013-05-15 Amylin Pharmaceuticals Llc Polypeptide conjugate
RU2422461C1 (ru) * 2010-02-09 2011-06-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Аналоги эксенатида
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
EP2714069A4 (en) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN103130889A (zh) * 2012-06-15 2013-06-05 中国药科大学 一种Exendin-4类似物及其制备方法和应用
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
AR096890A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
MX387560B (es) 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
US11123436B2 (en) 2015-07-24 2021-09-21 Hanmi Pharm. Co., Ltd. Method of preparing physiologically active polypeptide conjugate
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EP3368556B1 (en) * 2015-10-28 2024-04-10 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
JP2019536823A (ja) 2016-12-05 2019-12-19 ハンミ ファーマシューティカル カンパニー リミテッド 免疫反応が弱化された結合体
CN110545849A (zh) 2017-02-03 2019-12-06 韩美药品株式会社 具有增加的持续性的生理活性物质的缀合物及其应用
KR102629006B1 (ko) 2017-03-23 2024-01-25 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
KR20220092446A (ko) * 2020-12-24 2022-07-01 한미약품 주식회사 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
KR20230000682A (ko) 2021-06-25 2023-01-03 한미약품 주식회사 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
EP4504760A1 (en) * 2022-04-08 2025-02-12 Danmarks Tekniske Universitet Histidine methyltransferase for increased peptide and protein stability

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7A (en) * 1836-08-10 Thomas Blanchard Machine for boring holes and cutting lanyard-scores in deadeyes
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1997046584A1 (de) 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2002507188A (ja) 1996-08-30 2002-03-05 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド―１（ｇｌｐ―１）またはその同族体における外科処置後の異化変調を防止するための使用
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
DE122007000044I2 (de) * 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1938831A1 (en) 1997-08-08 2008-07-02 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
ES2293688T5 (es) * 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
US7220721B1 (en) * 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
JP2003522099A (ja) * 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
BR9913284A (pt) 1998-08-28 2001-05-15 Lilly Co Eli Métodos para administrar peptìdeos insulinotrópicos
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
PL209734B1 (pl) 2002-02-20 2011-10-31 Emisphere Tech Inc Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
EP1610811A4 (en) * 2002-12-17 2008-03-26 Amylin Pharmaceuticals Inc PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US8603972B2 (en) * 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
PL1971362T3 (pl) * 2005-08-19 2015-05-29 Amylin Pharmaceuticals Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
US20100016547A1 (en) 2005-11-30 2010-01-21 Takaomi Ito Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine

Also Published As

Publication number Publication date
EP2390265A2 (en) 2011-11-30
ZA201000125B (en) 2011-04-28
KR20090008151A (ko) 2009-01-21
RU2010101232A (ru) 2011-07-27
TWI532496B (zh) 2016-05-11
WO2009011544A3 (en) 2009-03-19
NZ582471A (en) 2012-01-12
JP6023516B2 (ja) 2016-11-09
EP2390265B1 (en) 2013-11-06
CN101778863A (zh) 2010-07-14
JP2015166368A (ja) 2015-09-24
JP2010533709A (ja) 2010-10-28
ES2528346T3 (es) 2015-02-09
BRPI0814097A8 (pt) 2016-01-12
CA2693154C (en) 2014-09-09
EP2176289A4 (en) 2010-10-27
RU2442792C2 (ru) 2012-02-20
SG10201510245SA (en) 2016-01-28
TW200922615A (en) 2009-06-01
CA2789123C (en) 2015-01-06
DK2390265T3 (da) 2014-02-10
SG183033A1 (en) 2012-08-30
TW201311272A (zh) 2013-03-16
JP2013014598A (ja) 2013-01-24
US9422349B2 (en) 2016-08-23
SG10201510249PA (en) 2016-01-28
PT2390265E (pt) 2014-02-12
EP2537860B1 (en) 2014-11-26
CA2693154A1 (en) 2009-01-22
JP5481377B2 (ja) 2014-04-23
NZ594853A (en) 2012-03-30
JP2013010779A (ja) 2013-01-17
EP2390265A3 (en) 2012-03-21
KR101231431B1 (ko) 2013-02-07
MY167486A (en) 2018-08-30
HK1207088A1 (en) 2016-01-22
ES2444622T3 (es) 2014-02-26
JP2009019027A (ja) 2009-01-29
PH12014500922A1 (en) 2016-03-07
AR067555A1 (es) 2009-10-14
AU2008276762A1 (en) 2009-01-22
PH12014500923A1 (en) 2016-03-07
CN104672319B (zh) 2020-03-10
NZ596828A (en) 2012-03-30
EP2176289A2 (en) 2010-04-21
JP6023515B2 (ja) 2016-11-09
TWI524896B (zh) 2016-03-11
IL203288A (en) 2016-02-29
EP2537861A1 (en) 2012-12-26
ES2528347T3 (es) 2015-02-09
JP2015172058A (ja) 2015-10-01
CA2789123A1 (en) 2009-01-22
EP2537861B1 (en) 2014-11-26
EP2537860A1 (en) 2012-12-26
TW201311273A (zh) 2013-03-16
TWI454276B (zh) 2014-10-01
US20100204451A1 (en) 2010-08-12
CA2789112A1 (en) 2009-01-22
JP2014094948A (ja) 2014-05-22
WO2009011544A2 (en) 2009-01-22
CN104672319A (zh) 2015-06-03
CA2789112C (en) 2015-01-20

Similar Documents

Publication Publication Date Title
BRPI0814097A2 (pt) Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado
DK2117338T3 (da) Delvist hydrolyseret kornprotein
EP2093287A4 (en) PEPTIDE BINDER IGG
DK3118220T3 (da) Protein
EP2118122A4 (en) NOVEL ANTIMICROBIAL PEPTIDES
EP2192109A4 (en) Bicyclic -amino acid derivative
BRPI0907363A2 (pt) Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal
DK2240595T4 (da) Glykosyleret proteinekspression i prokaryoter
EP2215246A4 (en) PROTEIN SCAFFOLDS
HRP20170138T1 (hr) Ponovno dobivanje proteina
IL221062B (en) Stitched polypeptides
SI2126093T1 (sl) Izboljšanje priprave proteinov
DK2035447T3 (da) Polypeptid
BRPI0914889A2 (pt) peptídeo glp-1 adicionado de cadeia oligossacarídica
BRPI0814971A2 (pt) Proteína
DK3115370T3 (da) Biologisk aktive peptider
EP2279202A4 (en) MULTIMER FORMS OF ANTIMICROBIAL PEPTIDES
BRPI1010661A2 (pt) peptídeo
EP2513137A4 (en) Saposin-a derived peptides and uses thereof
EP2348042A4 (en) MODIFIED AMYLOID BETA PEPTIDE
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider
EP2101804A4 (en) PROANGIOGENIC PEPTIDES
ATE547425T1 (de) Optimiertes dengue-virus-eintrittshemmendes peptid (dn81)
GB0706217D0 (en) Functional protein crystals
EP2252310A4 (en) HETEROCYCLIC PEPTIDE KETOAMIDE

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: A FIM DE ATENDER AS ALTERACOES DE NOME E ENDERECO REQUERIDAS ATRAVES DA PETICAO NO 20120115902/RJ, DE 13/12/2012, E NECESSARIO APRESENTAR MAIS UMA GUIA RELATIVA AO SEGUNDO SERVICO SOLICITADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]